Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 48, n° 4
pages 564-568 (avril 2003)
Doi : 10.1067/mjd.2003.169
Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas

Amy Krupnick Freeman, MDa, Gregory J. Linowski, BSb, Christopher Brady, BAa, Leah Lind, MPHc, Paul VanVeldhuisen, MSc, Giselle Singer, BSa, Mark Lebwohl, MDa
New York, New York, Deerfield, Illinois, and Rockville, Maryland 
From the Mount Sinai School of Medicine,a Fujisawa Healthcare Incorporated,b and the Emmes Corporation.c 


The safety and efficacy of 0.1% tacrolimus ointment for the treatment of psoriasis on the face, intertriginous areas, or both were evaluated in an open-label, clinical trial of 21 patients with psoriasis. Patients applied 0.1% tacrolimus ointment twice daily for 8 weeks. Efficacy was assessed through the investigator's evaluation of the individual signs and symptoms of psoriasis, and the physician's global evaluation of change in disease status. Assessments of cutaneous atrophy and other adverse events were made throughout the study to evaluate the safety of tacrolimus ointment. A total of 21 patients were enrolled in the study; 21 patients at least 18 years of age received study medication. Statistically significant improvement in the physician's assessment of the individual signs and symptoms was observed during the study. A total of 81% of patients (17 of 21) experienced complete clearance at day 57 (end of treatment). Only 2 patients reported adverse events, which were limited to itching and the feeling of warmth at the application site. None of the patients had atrophy, telangiectasia, or striae develop during the study. In summary, tacrolimus 0.1% ointment may be a safe and effective treatment option for patients with psoriasis on the face, intertriginous areas, or both. (J Am Acad Dermatol 2003;48:564-8.)

The full text of this article is available in PDF format.

 Original research supported by Fujisawa Healthcare Incorporated.
 Disclosure: Fujisawa Healthcare Incorporated has provided educational and research grants to the Department of Dermatology at Mount Sinai School of Medicine.
 Reprint requests: Mark Lebwohl, MD, 5 E 98th St, 12th Floor, The Mount Sinai School of Medicine, Department of Dermatology, New York, NY 10029. E-mail:
 0190-9622/2003/$30.00 + 0

© 2003  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline